2013 Polyamines Gordon Research Conference and Gordon Research Seminar
2013 Polyamines Gordon Research Conference and Gordon Research Seminar
批准号:
8528010
负责人:
John L. Cleveland
金额:
$1.5万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-05-17 至 2014-04-30
关键词:
AcademiaAgingApplications GrantsAsiaAutoimmune DiseasesAwardBacteriaBasic ScienceBiological ModelsBiologyCardiovascular DiseasesCell physiologyClinical OncologyClinical TrialsCollaborationsCommunicable DiseasesCommunitiesDevelopmentDiabetes MellitusDisabled PersonsDisciplineDiseaseEnvironmentEpigenetic ProcessEuropeFosteringFundingGenetic TranscriptionGoalsHomeostasisHumanInfusion proceduresInternationalIon ChannelIschemiaLifeLocationMalignant NeoplasmsMessenger RNAMetabolic DiseasesMetabolismMicroRNAsNeurodegenerative DisordersObesityOrganismParasitic infectionPathway interactionsPharmacologic SubstancePlantsPlayPolyaminesPostdoctoral FellowPreventionProtozoaRegulationRequest for ProposalsResearchResearch PersonnelResortRoleRunningScientistSeriesStructural BiologistStudentsTherapeuticTherapeutic AgentsTranslational ResearchTranslationsTravelVertebratesWorkYeastsanalogdata exchangedrug developmentexperienceforginggraduate studenthuman diseasemeetingsmultidisciplinarynext generationnotch proteinpathogenpolycationpostersprotein degradationpublic health relevancesmall moleculesuccesssymposiumtumorigenesis
中文摘要
描述(由申请人提供):多胺戈登研究会议(GRC)自1975年以来一直在举办,它提供了一个多学科论坛,聚集了顶尖的多胺研究人员以及年轻和成熟的研究人员,他们都是该领域的新手。2013年多胺GRC将于2013年6月16日至21日在华盛顿州沃特维尔山谷的沃特维尔山谷度假村举行,会议将集中讨论多胺途径在细胞生理学、发育和人类疾病中的调节和作用,以及针对多胺代谢的小分子作为癌症、传染病和代谢紊乱的治疗剂的使用和开发。GRC被一致认为是展示最好的多胺研究成果的卓越场所。多胺是存在于所有生命形式中的小的、基本的聚阳离子,但它们的调节在不同物种之间差异很大,在几种病理状态下,多胺的动态平衡被禁用。特别是,多胺在人类病原体中发挥着独特的作用,在缺血、心血管疾病、肥胖、糖尿病和癌症以及自身免疫和神经退行性疾病中,多胺代谢明显改变。因此,GRC将研究几种生物(脊椎动物、酵母、植物、原生动物和细菌)中的多胺的顶尖研究人员与那些评估治疗应用的人聚集在一起。这种科学学科的拼贴在GRC中是独一无二的,并创造了一个极具刺激性的环境,来自许多学科的专家,包括生物学家、化学家、结构生物学家和临床医生,以及来自学术界、生物技术和制药部门的研究人员。2013年多胺GRC将以处于基础和转译多胺研究前沿的科学家的演讲为特色,重点介绍多胺在肿瘤发生、代谢和传染病中的作用。会议将介绍多胺在基本细胞过程中的作用(例如,表观遗传学、转录、翻译、离子通道功能)、在发育和疾病中的作用、多胺稳态和运输的正常和异常控制、多胺靶向药物开发以及临床肿瘤学和传染病试验。特邀演讲者的演讲时间为30分钟,随后是10分钟的讨论时间。会议还将包括学生和博士后研究员的简短演讲,他们的工作是从海报演示中挑选出来的。会议期间将有两个海报会议。为了促进年轻科学家的参与,2013年GRC与第四届多胺戈登研究研讨会(GRS)同时举行。GRS为研究生和研究员提供了一个建设性的场所,促进在除少数资深同事以外的所有人缺席的情况下交换数据。GRS使GRC成为一种更丰富、更有建设性的经验,因为它促进了年轻科学家在主要会议期间的参与。GRS和GRC与会者之间的互动将促进新的研究想法、工具包和模型系统的共享,并将形成推动该领域向前发展的新的合作。
英文摘要
DESCRIPTION (provided by applicant): The Polyamines Gordon Research Conference (GRC) has continuously run since 1975, where it provides a multidisciplinary forum that brings together top polyamine researchers as well as young and established investigators new to the field. The 2013 Polyamines GRC will be held at Waterville Valley Resort in Waterville Valley, NH, from June 16-21, 2013, and it will be focused on the regulation and role of polyamine pathways in cell physiology, development and human disease, and on the use and development of small molecules targeting polyamine metabolism as therapeutic agents in cancer, infectious disease and metabolic disorders. The GRC is unanimously regarded as the pre-eminent venue for the presentation of the very best in polyamine research. Polyamines are small, essential polycations found in all forms of life, yet their regulation varies widely among species and polyamine homeostasis is disabled in several pathological states. In particular, polyamines play unique roles in human pathogens and polyamine metabolism is markedly altered in ischemia, cardiovascular disease, obesity, diabetes and cancer, and in autoimmune and neurodegenerative disorders. Thus, the GRC brings together top-notch researchers who study polyamines in several organisms (vertebrates, yeast, plants, protozoa and bacteria) with those assessing therapeutic applications. This collage of scientific disciplines is unique amongst GRCs and creates a remarkably stimulating environment, with experts from many disciplines, including biologists, chemists, structural biologists and clinicians, and investigators from both academia and the biotech and pharmaceutical sectors. The 2013 Polyamines GRC will feature presentations from scientists at the forefront of basic and translational polyamine research, with an emphasis on the role of polyamines in tumorigenesis and metabolic and infectious diseases. The meeting will include presentations on roles of polyamines in basic cellular processes (e.g., epigenetics, transcription, translation, ion channel function), in development and disease, the normal and aberrant control of polyamine homeostasis and transport, polyamine- targeted drug development and clinical oncology and infectious disease trials. Presentations by invited speakers will be 30 minutes, followed by 10-minute discussion period. Sessions will also include short talks by students and postdoctoral fellows whose work is chosen from poster presentations. There will be two poster sessions during the meeting. To foster participation of young scientists, the 2013 GRC is held in conjunction with the 4th Polyamines Gordon Research Seminar (GRS). The GRS provides graduate students and fellows with a constructive venue that fosters the exchange of data in the absence of all but a few senior colleagues. The GRS has made the GRC a richer, more constructive experience, as it promotes the participation of young scientists during the main conference. The interactions between GRS and GRC conferees will facilitate the sharing of new research ideas, toolsets and model systems and will forge new collaborations that will to drive the field forward.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 3
-
批准号:10171101
-
项目类别:
-
资助金额:$34.5万
-
财政年份:2021
-
负责人:John L. Cleveland
-
依托单位:
Project 3
-
批准号:10438715
-
项目类别:
-
资助金额:$33.98万
-
财政年份:2021
-
负责人:John L. Cleveland
-
依托单位:
Project 3
-
批准号:10676736
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2021
-
负责人:John L. Cleveland
-
依托单位:
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
-
批准号:10153731
-
项目类别:
-
资助金额:$55.47万
-
财政年份:2020
-
负责人:John L. Cleveland
-
依托单位:
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
-
批准号:10405450
-
项目类别:
-
资助金额:$54.36万
-
财政年份:2020
-
负责人:John L. Cleveland
-
依托单位:
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
-
批准号:10653834
-
项目类别:
-
资助金额:$54.36万
-
财政年份:2020
-
负责人:John L. Cleveland
-
依托单位:
Epigenetic Regulation of Drug Resistance to ABT-199 in B-cell Malignancies
-
批准号:9904591
-
项目类别:
-
资助金额:$18.71万
-
财政年份:2019
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:10524031
-
项目类别:
-
资助金额:$71.49万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:9710619
-
项目类别:
-
资助金额:$72.95万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:10064576
-
项目类别:
-
资助金额:$72.95万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
-
批准号:10307616
-
项目类别:
-
资助金额:$71.49万
-
财政年份:2018
-
负责人:John L. Cleveland
-
依托单位:
High Throughput Screening to Discover Ulk1 Kinase Inhibitors
-
批准号:9228381
-
项目类别:
-
资助金额:$45.31万
-
财政年份:2015
-
负责人:John L. Cleveland
-
依托单位:
High Throughput Screening to Discover Ulk1 Kinase Inhibitors
-
批准号:9020250
-
项目类别:
-
资助金额:$45.31万
-
财政年份:2015
-
负责人:John L. Cleveland
-
依托单位:
High-throughput assay development for molecular probes targeting the ULK1 kinase
-
批准号:8346406
-
项目类别:
-
资助金额:$47.71万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics
-
批准号:8597537
-
项目类别:
-
资助金额:$74.76万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis
-
批准号:8284008
-
项目类别:
-
资助金额:$41.09万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics
-
批准号:8239135
-
项目类别:
-
资助金额:$79.38万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis
-
批准号:8886095
-
项目类别:
-
资助金额:$1.34万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
High-throughput assay development for molecular probes targeting the ULK1 kinase
-
批准号:8676481
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
Myc-directed control of mRNA turnover in lymphopoiesis and lymphomagenesis
-
批准号:8446311
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2012
-
负责人:John L. Cleveland
-
依托单位:
海外基金